CompletedPHASE1, PHASE2NCT01445080
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Studying Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Brigitte C WidemannCOG Phase I Consortium
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 70 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2006 – 2012
Study locations (25)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University/Herbert Irving Cancer Center, New York, New York, United States
- State University of New York Upstate Medical University, Syracuse, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01445080 on ClinicalTrials.govOther trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05031897Two Step Haplo With Radiation ConditioningThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT04188405Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02530034Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03630991Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02861417Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center
See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2) →